A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Official Title

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

Summary:

The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.

Trial Description

Primary Outcome:

• Objective response rate (ORR)

Secondary Outcome:

• Progression free survival (PFS)
• Duration of response (DOR)
• Time to response (TTR)
• Incidence, timing, severity of treatment-emergent adverse events (TEAEs)

This is an open-label, randomized active control study of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed or refractory follicular lymphoma. Randomization is 2:1 and participants will be stratified by the number of prior lines of therapy (2

• 3 vs > 3),rituximab-refractory status and geographic region (China vs ex-China). The study will evaluate the efficacy, as measured by overall response rate by independent review, safety and tolerability. Pharmacokinetic profile of BGB-3111 and obinutuzumab combination therapy will also be evaluated

View this trial on ClinicalTrials.gov